CL2017002796A1 - Una composición farmacéutica antiviral de uso tópico. - Google Patents

Una composición farmacéutica antiviral de uso tópico.

Info

Publication number
CL2017002796A1
CL2017002796A1 CL2017002796A CL2017002796A CL2017002796A1 CL 2017002796 A1 CL2017002796 A1 CL 2017002796A1 CL 2017002796 A CL2017002796 A CL 2017002796A CL 2017002796 A CL2017002796 A CL 2017002796A CL 2017002796 A1 CL2017002796 A1 CL 2017002796A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
antiviral pharmaceutical
topical antiviral
conditional
topical
Prior art date
Application number
CL2017002796A
Other languages
English (en)
Inventor
Luis Alberto Argañarás
Original Assignee
Quim Luar S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quim Luar S R L filed Critical Quim Luar S R L
Publication of CL2017002796A1 publication Critical patent/CL2017002796A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • A61K31/78Polymers containing oxygen of acrylic acid or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Abstract

<p>UNA COMPOSICIÓN FARMACÉUTICA ANTIVIRAL DE USO TÓPICO CONTRA AQUELLOS VIRUS CON ENVOLTURA LIPÍDICA, QUE COMPRENDE COMO PRINCIPIOS ACTIVOS UN COPOLÍMERO CATIÓNICO 5 CONTENIENDO GRUPOS AMINOS TERCIARIOS, Y UN TENSIOACTIVO CATIÓNICO CONTENIENDO GRUPOS AMONIOS CUATERNARIOS.</p>
CL2017002796A 2015-05-15 2017-11-06 Una composición farmacéutica antiviral de uso tópico. CL2017002796A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP150101519A AR100459A1 (es) 2015-05-15 2015-05-15 Una composición farmacéutica antiviral de uso tópico

Publications (1)

Publication Number Publication Date
CL2017002796A1 true CL2017002796A1 (es) 2018-07-13

Family

ID=57319498

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002796A CL2017002796A1 (es) 2015-05-15 2017-11-06 Una composición farmacéutica antiviral de uso tópico.

Country Status (11)

Country Link
US (1) US10478452B2 (es)
EP (1) EP3295934B1 (es)
AR (1) AR100459A1 (es)
BR (1) BR112017024399B1 (es)
CL (1) CL2017002796A1 (es)
CO (1) CO2017011297A2 (es)
ES (1) ES2915824T3 (es)
IL (1) IL255635A (es)
MX (1) MX2017014162A (es)
PE (1) PE20180396A1 (es)
WO (1) WO2016185069A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022219944A1 (ja) * 2021-04-16 2022-10-20 株式会社日本触媒 抗コロナウイルス剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743727A (en) * 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US4902720A (en) * 1983-01-10 1990-02-20 Baldone Joseph A Treatment of virus infections with quaternary ammonium compounds
US5160737A (en) * 1988-05-03 1992-11-03 Perio Products Ltd. Liquid polymer composition, and method of use
BRPI0014271B1 (pt) * 1999-09-24 2021-06-22 Janssen Pharmaceutica N.V. Partícula consistindo em uma dispersão de sólidos, uso da dita partícula, dispersão de sólidos, forma de dosagem farmacêutica, bem como processos de preparação de dita partícula, dispersão e forma de dosagem
US6855341B2 (en) 2002-11-04 2005-02-15 Jeffrey B. Smith Anti-viral compositions and methods of making and using the anti-viral compositions
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
ITMI20051417A1 (it) * 2005-07-22 2007-01-23 Mipharm S P A Formulazione topica in forma di gel contenente come ingredienti attivi ciclovit e lidocaina
US8119115B2 (en) * 2006-02-09 2012-02-21 Gojo Industries, Inc. Antiviral method
US7883487B2 (en) * 2008-06-16 2011-02-08 Shantha Totada R Transdermal local anesthetic patch with injection port
US20140328895A1 (en) * 2011-03-29 2014-11-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Film-forming composition for a ph-dependant sustained release of the active agent

Also Published As

Publication number Publication date
MX2017014162A (es) 2018-06-20
WO2016185069A1 (es) 2016-11-24
US20180250327A1 (en) 2018-09-06
CO2017011297A2 (es) 2018-01-31
BR112017024399A2 (pt) 2019-02-05
IL255635A (en) 2018-01-31
EP3295934A1 (en) 2018-03-21
EP3295934B1 (en) 2022-03-02
ES2915824T3 (es) 2022-06-27
EP3295934A4 (en) 2019-01-02
BR112017024399B1 (pt) 2022-06-07
AR100459A1 (es) 2016-10-05
PE20180396A1 (es) 2018-02-28
US10478452B2 (en) 2019-11-19

Similar Documents

Publication Publication Date Title
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2016000381A1 (es) Compuestos antivirales
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
BR112015009189A2 (pt) conjunto de potência para um autoinjetor e autoinjetor que contém o mesmo
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
BR112018003110A2 (pt) nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CU20160187A7 (es) (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13, 13a-octahidro-2,5-metanopirido[1&#39;,2&#39;:4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodio
BR112018011122A2 (pt) antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
BR112015027321A8 (pt) Compostos e composições para modular a expressão de apolipoproteína(a) e seus usos
BR112015018161A2 (pt) Conjugado de oligômeros antisense de lna, composição farmacêutica e uso de um conjugado de oligômeros antisense de lna
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4&#39; -difluorometilo como inhibidores de la replicación de arn de la influenza.
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
BR112018002983A2 (pt) composição compreendendo uma lactama e um álcool
BR112015000520A2 (pt) agente de espessamento estável com lipase
BR112016006048A8 (pt) composições antimicrobianas
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
CL2017000394A1 (es) Composición que contiene cineol para la administración nasal
MX2017009812A (es) Composiciones y metodos para inhibir infeccion viral.
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
CR20150145A (es) Composiciones con matriz de resina fundida en caliente